Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): The phase III randomized MELT trial

American Journal of Transplantation

Volumn 13, Issue 3, 2013, Pages 760-769

  Bunnapradist, S ^a   Ciechanowski, K ^b   West Thielke, P ^c   Mulgaonkar, S ^d   Rostaing, L ^e   Vasudev, B ^f   Budde, K ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^d Saint Barnabas Health Care System   (United States)

^e CHU RANGUEIL   (France)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Conversion; immunosuppression; kidney transplantation; tacrolimus

Indexed keywords

TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HEART ARREST; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; LIMB PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SURVIVAL; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84874412306     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12035     Document Type: Article

References (22)

1. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC,. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; Oct 19; (4): CD003961.
2. 2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI.
3. Kershner RP, Fitzsimmons WE,. Relationship of Fk506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-926.
4. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ,. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 1576-1581.
5. Langton AK, Griffiths CE, Sherratt MJ, Watson RE,. Cross-linking of structural proteins in ageing skin: An in situ assay for the detection of amine oxidase activity. Biogerontology 2012. Aug 26. [Epub ahead of print].
6. Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T,. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757-2763.
7. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR,. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-1884.
8. Claxton AJ, Cramer J, Pierce C,. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001; 23: 1296-1310.
9. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC,. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22-e33.
10. Morrissey PE, Reinert S, Yango A, Gautam A, Monaco A, Gohh R,. Factors contributing to acute rejection in renal transplantation: The role of noncompliance. Transplant Proc 2005; 37: 2044-2047.
11. Michelon T, Dominguez V, Losekan A, et al. Kidney graft failure due to noncompliance. Transplant Proc 1999; 31: 3031-3032.
12. Alloway RR, Mulgaonkar S, Bowers VD, al. e. A phase 2b, open-label, multi-center, prospective, randomized study to compare the pharmacokinetics and safety of LCP-Tacro™ tablets once-a-day to Prograf® capsules twice-a-day in de novo kidney transplant patients. Am J Transplant 2009; 9 (Suppl 2): 414.
13. Alloway R, Mulgaonkar S, Ueda K, Cohen D, B. K. A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-Tacro tablets once-a-day vs. Prograf capsules twice-a-day in de novo kidney transplants. Am J Transplant 2011; 11 (Suppl 2): 355.
14. Neylan JF,. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Clin Transplant 1998; 65: 515-523.
15. Paris M, Rouleau M, Puceat M, Aberdam D,. Regulation of skin aging and heart development by TAp63. Cell death and differentiation. 2012; 19: 186-193.
16. Feldman HI, Hackett M, Bilker W, Strom BL,. Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents. Pharmacoepidemiol Drug Saf 1999; 8: 1-14.
17. Germani G, Lazzaro S, Gnoato F, et al. Nonadherent behaviors after solid organ transplantation. Transplant Proc 2011; 43: 318-323.
18. Chisholm MA,. Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs 2002; 62: 567-575.
19. Laederach-Hofmann K, Bunzel B,. Noncompliance in organ transplant recipients: A literature review. General Hospital Psychiatr 2000; 22: 412-424.
20. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
21. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004; 4: 237-243.
22. Holdaas H, Rostaing L, Serõn D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation 2011; 92: 410-418.